Skip to main content
SpringerLink
Log in

Treatment of Psychosis in Parkinson’s Disease

Safety Considerations

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Psychosis only rarely occurs in patients with untreated Parkinson’s disease. Much more commonly, psychosis is induced by drug therapy for Parkinson’s disease and is the strongest known risk factor for nursing home placement. Delusions are less frequent than hallucinations, but are more concerning as they are often paranoid in nature. Treatment begins with a search for correctable infectious, toxic, and metabolic aetiologies. If symptoms persist, anti-Parkinson’s disease medications are slowly reduced. However, withdrawal of these drugs usually worsens parkinsonism and is often not tolerated. Certain atypical antipsychotics can be used to treat psychosis without compromising motor function.

The choice of atypical antipsychotic is largely based on ease of use and adverse effect profile as most have comparable efficacy in improving psychosis. Currently, there are five marketed atypical drugs — clozapine, risperidone, olanzapine, quetiapine and ziprasidone. Ziprasidone is the only agent whose adverse effect profile has not been reported in Parkinson’s disease.

The most common adverse effects of clozapine in Parkinson’s disease are sedation, orthostatic hypotension and sialorrhoea. Sedation is generally helpful since these patients are frequently awake at night and tend to have worse behavioural problems then. Clozapine does not induce deterioration of motor function, but it has the potential to cause agranulocytosis, which is idiosyncratic and not dose-related.

In risperidone-treated Parkinson’s disease patients, reported adverse effects include somnolence, sialorrhoea, dizziness, palpitations, constipation, delirium, fatigue, leg cramps, depression, urinary incontinence and hypotension. Although in some Parkinson’s disease studies, risperidone has been well tolerated, others have shown that many patients are unable to tolerate the drug due to deterioration of motor function.

While an initial study of olanzapine in Parkinson’s disease psychosis showed the drug to be effective without deterioration of motor function, succeeding reports demonstrated a deleterious effect of the drug on motor functioning.

The most common adverse effects of quetiapine in Parkinson’s disease patients are sedation and orthostatic hypotension. There is a lack of double-blind trials; however, cumulative reports involving >200 Parkinson’s disease patients strongly suggest that quetiapine is well tolerated and effective. Unlike clozapine, it does not improve tremor and may induce mild deterioration of motor function.

Recently, cholinesterase inhibitors have been reported to alleviate psychosis in Parkinson’s disease. Although ondansetron, an antiemetic with antiserotonergic properties, has been reported to relieve psychosis in Parkinson’s disease, its prohibitive cost has prevented further study in this population. Electroconvulsive treatment is generally reserved for the patient with psychotic depression who is unable to tolerate any pharmacological therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Regis E. Precis de Psychiatrie. Paris: Gaston Doiz, 1906

    Google Scholar 

  2. Jacson J, Free G, Pike H. The psychiatric manifestations in paralysis agitans. Arch Neurol Psychiatry 1923; 10: 680–4

    Article  Google Scholar 

  3. Friedman J. The management of levodopa psychoses. Clinical Neuropharmacol 1991; 14: 283–95

    Article  CAS  Google Scholar 

  4. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. In: Narabayashi N, Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in neurology, Parkinson’s disease: from basic research to treatment. New York; Raven Press, 1993: 702–6

    Google Scholar 

  5. Melamed E, Achiron A, Shapira A, et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991; 14: 273–8

    Article  PubMed  CAS  Google Scholar 

  6. Klawans H. Levodopa-induced psychosis. Psychiatr Ann 1978; 8: 447–71

    Google Scholar 

  7. Fischer P, Danielczyk W, Simanyi M, Streifler M. Dopaminergic psychosis in advanced Parkinson’s disease. In: Streifler M, Korczyn A, Melamed E, Youdim M, editors. Advances in neurology. Vol. 53. Parkinson’s disease: anatomy, pathology and therapy. New York: Raven Press, 1990: 391–7

    Google Scholar 

  8. Cumming J. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc 1991; 33: 708–16

    Google Scholar 

  9. Fernandez H, Friedman J. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999; 11(6): 467–83

    Article  CAS  Google Scholar 

  10. Goetz C, Stebbins G. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227–9

    Article  PubMed  CAS  Google Scholar 

  11. Aarsland D, Larsen J, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population based prospective study. J Am Geriatr Soc 2000; 48: 938–42

    PubMed  CAS  Google Scholar 

  12. Liu K, Manton K. The characteristics and utilization pattern of an admission cohort of nursing home patients. Gerontologist 1983; 23: 92–8

    Article  PubMed  CAS  Google Scholar 

  13. Goetz C, Stebbins G. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 1995; 45: 669–71

    Article  PubMed  CAS  Google Scholar 

  14. Mendis T, Barclay C, Mohr E. Drug-induced psychosis in Parkinson’s disease: a review of management. CNS Drugs 1996; 5(3): 166–74

    Article  CAS  Google Scholar 

  15. Friedman J, Fernandez H. The non-motor problems of Parkinson’s disease. Neurologist 2000; 6: 18–27

    Article  Google Scholar 

  16. Nausieda P, Weiner W, Kaplan L, et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 1982; 5: 183–94

    Article  PubMed  CAS  Google Scholar 

  17. Comella C, Tanner C, Ristanovic R. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710–4

    Article  PubMed  CAS  Google Scholar 

  18. Sanchez-Ramos J, Ortoll R, Paulson G. Visual hallucinations associated with Parkinson’s disease. Arch Neurol 1996; 53: 1265–8

    Article  PubMed  CAS  Google Scholar 

  19. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733–45

    Article  PubMed  Google Scholar 

  20. Inzelberg R, Kiervasse S, Korczyn A. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 533–5

    Article  PubMed  CAS  Google Scholar 

  21. Aarsland D, Larsen J, Cummings J, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: a community-based study. Arch Neurol 1999; 56: 595–601

    Article  PubMed  CAS  Google Scholar 

  22. Factor S, Friedman J. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12(4): 483–96

    Article  PubMed  CAS  Google Scholar 

  23. Factor S, Molho E, Podskalny G, et al. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115–38

    PubMed  CAS  Google Scholar 

  24. Wolters E, Hurwitz T, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832–4

    Article  PubMed  CAS  Google Scholar 

  25. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757–63

    Google Scholar 

  26. French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999; 353: 2041–2

    Google Scholar 

  27. Ostergaard K, Dupont E. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson’s disease. Acta Neurol Scand 1988; 78: 349–50

    Article  PubMed  CAS  Google Scholar 

  28. Kahn N, Freeman A, Juncos J, et al. Clozapine is beneficial for psychosis in Parkinson’s disease. Mov Disord 1992; 41: 1699–700

    Google Scholar 

  29. Factor S, Brown D, Molho E, et al. Clozapine: a two-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544–6

    Article  PubMed  CAS  Google Scholar 

  30. Rabey J, Treves T, Neufeld M, et al. Low-dose clozapine in the treatment of levodopa -induced mental disturbances in Parkinson’s disease. Neurology 1995; 45: 432–4

    Article  PubMed  CAS  Google Scholar 

  31. Ruggieri S, De Pandis M, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacol 1997; 20: 204–9

    Article  PubMed  CAS  Google Scholar 

  32. Meco G, Allesandri A, Bonifati V, et al. Risperidone for hallucinations in levodopa treated Parkinson’s disease patients. Lancet 1994; 343: 1370–1

    Article  PubMed  CAS  Google Scholar 

  33. Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease [letter]. Lancet 1994; 344: 681

    Article  PubMed  CAS  Google Scholar 

  34. Rich SS, Friedman JH, Ott BR. Risperidone vs clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12): 556–9

    PubMed  CAS  Google Scholar 

  35. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson’s disease: an open-label, long-term study. Mov Disord 1997; 12(4): 1241–54

    Article  Google Scholar 

  36. Workman RH, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1997; 9(4): 594–7

    PubMed  CAS  Google Scholar 

  37. Leopold N. Risperidone treatment of drug-related psychosis in patients with Parkinsonism. Mov Disord 2000; 15(2): 301–4

    Article  PubMed  CAS  Google Scholar 

  38. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord 2000; 15(6): 1230–7

    Article  PubMed  CAS  Google Scholar 

  39. Wolters EC, Jansen ENH, Tuynman-Qua G, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47: 1085–7

    Article  PubMed  CAS  Google Scholar 

  40. Jimenez-Jimenez F, Talon-Barranco A, Orti-Pareja EA. Olanzapine can worsen parkinsonism. Neurology 1998; 50: 1183–4

    Article  PubMed  CAS  Google Scholar 

  41. Friedman JH, Goldstein S. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1998; 50: 1195–6

    Article  PubMed  CAS  Google Scholar 

  42. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open-label pilot trial. Clin Neuropharmocol 1998; 21: 285–8

    CAS  Google Scholar 

  43. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999; 14: 1014–6

    Article  PubMed  CAS  Google Scholar 

  44. Weiner WJ, Minaga A, Shulma L. Olanzapine for the treatment of hallucinations/delusions in Parkinson’s disease [abstract]. Mov Disord 1998; 13Suppl. 2: 62

    Google Scholar 

  45. Churchyard A, Iansek R. Olanzapine as treatment of the neuropsychiatric complications of Parkinson’s disease: an open-label study [abstract]. Mov Disord 1998; 13Suppl. 2: 62

    Google Scholar 

  46. Graham J, Sussman J, Ford K, et al. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson’s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998; 65: 774–7

    Article  PubMed  CAS  Google Scholar 

  47. Stover N, Juncos J. Olanzapine treatment of parkinsonian patients with psychosis [abstract]. Neurology 1999; 52Suppl. 2:A215

    Google Scholar 

  48. Goetz C, Blasucci L, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789–94

    Article  PubMed  CAS  Google Scholar 

  49. Aarsland D, Larsen J, Lim N, et al. Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 392–4

    PubMed  CAS  Google Scholar 

  50. Gimenez-Roldan S, Mateo D, Navarro E, et al. Efficacy and safety of clozapine and olanzapine: an open label trial comparing two groups of Parkinson’s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001; 7: 121–7

    Article  PubMed  Google Scholar 

  51. Parsa M, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1998; 10: 216–9

    PubMed  CAS  Google Scholar 

  52. Evatt M, Lewart D, Juncos J. ‘Seroquel’ treatment of psychosis in parkinsonism [abstract]. Mov Disord 1996; 11: 595

    Google Scholar 

  53. Juncos J, Arvantis L, Swertzer D, et al. Quetiapine improves psychotic symptoms associated with Parkinson’s disease [abstract]. Neurology 1999; 52Suppl. 2: A262

    Google Scholar 

  54. Juncos J, Evatt M, Jewart D. Long term effect of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998; 50: A70–1

    Google Scholar 

  55. Samanta J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson’s disease [abstract]. Mov Disord 1998; 13Suppl. 2: 274

    Google Scholar 

  56. Fernandez H, Lannon M, Friedman J, et al. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 579–81

    Article  PubMed  CAS  Google Scholar 

  57. Targum S, Abbott J. Efficacy of quetiapine in Parkinson’s patients with psychosis. J Clin Psychopramacol 2000; 20: 54–60

    Article  CAS  Google Scholar 

  58. Reddy S, Factor S, Molho E, et al. The effect of quetiapine on psychosis and motor function in patients with and without dementia. Mov Disord 2002; 17: 676–81

    Article  PubMed  Google Scholar 

  59. Dewey R, O’Suilleabhain PE. Treatment of drug induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2000; 55: 1753–4

    Article  PubMed  Google Scholar 

  60. Fernandez H, Trieschmann M, Burke M, Jacques C, Friedman J. Long-term quetiapine use for drug induced psychosis among parkinsonian patients. Mov Disord. In press

  61. McKeith I, Del Ser T, Spano P. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6

    Article  PubMed  CAS  Google Scholar 

  62. McClean L, Collins C, Byrne E. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms and sleep. Int Psychogeriatr 2001; 13: 277–88

    Article  Google Scholar 

  63. Grace J, Daniel S, Steven T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13: 199–205

    Article  PubMed  CAS  Google Scholar 

  64. Rojas-Fernandez C. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001; 35: 202–5

    Article  PubMed  CAS  Google Scholar 

  65. Melamed E, Zoldan J, Friedberg G, et al. Is hallucinosis in Parkinson’s disease due to central serotonergic hyperactivity? Mov Disord 1993; 8: 406–7

    Google Scholar 

  66. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Odansetron for hallucinosis in advanced Parkinson’s disease. Lancet 1993; 341: 562–3

    Article  PubMed  CAS  Google Scholar 

  67. Hurwitz T, Calne D, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15: 32–4

    PubMed  CAS  Google Scholar 

  68. Douyen R, Serby M, Klutcho B, et al. ECT and Parkinson’s disease revisited: a naturalistic study. Am J Psychiatry 1989; 146: 1451–5

    Google Scholar 

  69. Balldin J, Eden S, Granerus A, et al. Electroconvulsive therapy in Parkinson’s syndrome with ‘on-off’ phenomenon. J Neural Transm 1980; 47: 11–21

    Article  PubMed  CAS  Google Scholar 

  70. Andersen K, Balldin J, Gottfires C, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson’s disease with on-off phenomena. Acta Neurol Scand 1987; 76: 191–9

    Article  PubMed  CAS  Google Scholar 

  71. Sifton D, editor. Physicians’ desk reference. Montvale (NJ): Medical Economics Company Inc., 2002

    Google Scholar 

  72. Friedman J, Lannon M. Clozapine treatment of tremor in Parkinson’s disease. Mov Disord 1990; 5: 225–9

    Article  PubMed  CAS  Google Scholar 

  73. Diederich N, Keipes M, Grass M, et al. La clozapine dans le traitement des manifestations psychiatriques de la maladie de Parkinson. Rev Neurol 1995; 151: 251–7

    PubMed  CAS  Google Scholar 

  74. Pacia S, Devinsky O. Clozapine-related seizures: experience with 5629 patients. Neurology 1994; 44: 2247–9

    Article  PubMed  CAS  Google Scholar 

  75. Koller W, Pahwa R, Lyons K, et al. Low dose clozapine in the treatment of levodopa-induced psychosis [abstract]. Mov Disord 1994; 9Suppl. 1: 64

    Google Scholar 

  76. Factor S, Brown D. Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disord 1992; 7: 125–31

    Article  PubMed  CAS  Google Scholar 

  77. Trosch R, Friedman J, Lannon M, et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13: 377–82

    Article  PubMed  CAS  Google Scholar 

  78. Russel I, Mackell I. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–51

    Article  Google Scholar 

  79. Fernandez H, Friedman J, Factor S, et al. New onset diabetes among parkinsonian patients on long-term clozapine use. 7th International Congress on Parkinson’s Disease and Movement Disorders; 2002 Nov 10-14; Miami (FL)

  80. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a 5-year naturalistic study. Am J Psychol 2000; 157(6): 975–81

    Article  CAS  Google Scholar 

  81. Rudolf J, Grond M, Neveling M, et al. Clozapine-induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J Neural Transm 1997; 104: 1305–11

    Article  PubMed  CAS  Google Scholar 

  82. Wagner M, Defilippi J, Menza M, et al. Clozapine for the treatment of psychosis in Parkinson’s disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996; 8: 276–80

    PubMed  CAS  Google Scholar 

  83. Goetz C, Koller W, Poewe W, et al. Management of Parkinson’s disease: an evidence based review. Mov Disord 2002; 17Suppl. 4: s120–7

    Google Scholar 

  84. Fernandez H, Donnelly E, Friedman J. Long-term outcome of clozapine use for psychosis among parkinsonian patients. 7th International Congress on Parkinson’s Disease and Movement Disorders; 2002 Nov 10-14; Miami (FL)

  85. Keyser D, Rodnitzky R. Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991; 151: 794–6

    Article  PubMed  CAS  Google Scholar 

  86. Henderson V, Wooten G. Neuroleptic malignant syndrome: a pathogenetic role for dopamine blockade? Neurology 1981;31: 132–7

    Article  PubMed  CAS  Google Scholar 

  87. Pfeiffer R, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson’s disease. Mov Disord 1990; 5: 239–42

    Article  PubMed  CAS  Google Scholar 

  88. Marder S, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825–35

    PubMed  CAS  Google Scholar 

  89. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55

    Article  PubMed  Google Scholar 

  90. Bondolfi G, Dufour H, Patris M, et al. Risperidone vs clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155(4): 499–504

    PubMed  CAS  Google Scholar 

  91. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2000; 12(3): 364–9

    Article  PubMed  CAS  Google Scholar 

  92. Whitten JR, Ruehter VL. Risperidone and hyponatremia: a case report. Ann Clin Psychiatry 1997; 9(3): 181–3

    PubMed  CAS  Google Scholar 

  93. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15(2): 201–11

    Article  PubMed  CAS  Google Scholar 

  94. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease [letter]. Mov Disord 2001; 17(1): 221–5

    Article  Google Scholar 

  95. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782–5

    Article  PubMed  CAS  Google Scholar 

  96. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59(2): 69–75

    Article  PubMed  CAS  Google Scholar 

  97. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22(3): 475–83

    Article  PubMed  CAS  Google Scholar 

  98. Saran BM. Risperidone-induced tardive dyskinesia [letter]. J Clin Psychiatry 1998; 59 (1): 29–30

    Article  Google Scholar 

  99. Buzan RD. Risperidone-induced tardive dyskinesia [letter]. Am J Psychiatry 1996; 153 (5): 734–5

    Google Scholar 

  100. Gwinn KA, Caviness J. Risperidone-induced tardive dyskinesia and Parkinsonism. Mov Disord 1997; 12(1): 119–21

    Article  PubMed  CAS  Google Scholar 

  101. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57Suppl. 11: 4–11

    PubMed  CAS  Google Scholar 

  102. Beasley CM, Tollefson G, Tran P, et al. Olanzapine vs placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14(2): 111–23

    Article  PubMed  CAS  Google Scholar 

  103. Beasley CM, Hamilton S, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125–37

    Article  PubMed  CAS  Google Scholar 

  104. Tollefson G, Beasley CM, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154(4): 457–65

    PubMed  CAS  Google Scholar 

  105. Beasley CM, Tollefson G, Tran P. Safety of olanzapine. J Clin Psychiatry 1997; 58Suppl. 10: 13–7

    PubMed  CAS  Google Scholar 

  106. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159–67

    Article  PubMed  CAS  Google Scholar 

  107. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11): 1686–96

    PubMed  CAS  Google Scholar 

  108. Wirshing D, Spellberg B, Erhart S, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44(8): 778–83

    Article  PubMed  CAS  Google Scholar 

  109. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55: 795–9

    Article  PubMed  CAS  Google Scholar 

  110. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63Suppl. 4: 12–9

    PubMed  CAS  Google Scholar 

  111. Somer B. Quetiapine induced extrapyramidal side effects in patients with Parkinson’s disease: case report. J Geriatric Psychiatry Neurol 2001; 14: 99–100

    Article  Google Scholar 

  112. Raja M, Azzoni A. Novel antipsychotics and acute dystonic reactions. Int J Neuropsychopharmacol 2001; 4: 393–7

    Article  PubMed  CAS  Google Scholar 

  113. Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8(2): 153–62

    Article  CAS  Google Scholar 

  114. Glassman A, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 1774–82

    Article  PubMed  CAS  Google Scholar 

  115. Daniel DG, Zimbroff DL, Potkin S, et al. Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20(5): 491–505

    Article  PubMed  CAS  Google Scholar 

  116. Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63 (6): 516–23

    Article  Google Scholar 

  117. Tandon R, Harrigan EP, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159–77

    Google Scholar 

  118. Keck PJ, Buffenstien A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbationof schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173–84

    Article  PubMed  CAS  Google Scholar 

  119. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8(2): 81–98

    Article  PubMed  Google Scholar 

  120. Zoldan Y, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson’s disease: treatment with odansetron, a 5HT3 receptor antagonist. Neurology 1995; 45: 1305–8

    Article  PubMed  CAS  Google Scholar 

  121. Eichhorn T, Brunt E, Oertel W. Odansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47: 1608–9

    Article  PubMed  CAS  Google Scholar 

  122. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984; 15: 415–8

    Article  PubMed  CAS  Google Scholar 

  123. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61: 324–5

    Article  PubMed  CAS  Google Scholar 

  124. Werber E, Rabey J. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm 2001; 108: 1319–25

    Article  PubMed  CAS  Google Scholar 

  125. Reading P, Luce A, McKeith I. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171–4

    Article  PubMed  CAS  Google Scholar 

  126. McKeith I, Newby V, Wilkinson L, et al. Eisai protocol E2020-E044-316: open label donepezil trial in the treatment of dementia with Lewy bodies and Parkinson’s disease. Presented at the EISAI Investigators Meeting 2002; Mar 3: Monte Carlo

  127. Van Laar T, de Vries J, Nakhosteen A, et al. Rivastigmine as anti-psychotic treatment in patients with Parkinson’s disease. Parkinsonism Relat Disord 2001; 7: 573

    Google Scholar 

  128. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25: 107–10

    Article  PubMed  CAS  Google Scholar 

  129. Aarsland D, Laake K, Larsen J, et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708–12

    Article  PubMed  CAS  Google Scholar 

  130. Pourcher E. Cholinesterase inhibitor: an exploratory trial in ldopa induced hallucinations [abstract]. Mov Disord 2001; 16Suppl. 1: S34

    Google Scholar 

  131. Richard I, Justus A, Greig N, et al. Rivastigmine worsening of motor function and mood in a patient with Parkinson’s disease. Mov Disord 2001; 16Suppl. 1: 533–4

    Google Scholar 

  132. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23: 41–3

    Article  PubMed  CAS  Google Scholar 

  133. Ott B, Lannon M. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992; 15(4): 322–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Hubert H. Fernandez has, over the past 4 years, been a paid consultant, paid speaker or performed clinical research under contract for the following companies: AstraZeneca, Aventis, Novartis, Teva, GlaxoSmithKline, Elan, Mylan, Cephalon, Inc, Amarin, and Merck KgaA; however, this author has no owner interest in any pharmaceutical company. Martha E. Trieschmann has no conflicts of interest to disclose. Joseph H. Friedman has, over the past 5 years, been a paid consultant, paid speaker or performed clinical research under contract for the following companies: AstraZeneca, Aventis, Boehringer Ingelheim, BristolMyers-Squibb, Eli Lilly, Merck KgaA, Novartis, Pfizer, PPD Development, Teva, Pharmacia and Janssen; however, this author has no owner interest in any pharmaceutical company.

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA

    Hubert H. Fernandez, Martha E. Trieschmann & Joseph H. Friedman

Authors
  1. Hubert H. Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martha E. Trieschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph H. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert H. Fernandez.

Additional information

Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, 111 Brewster Street, RI 02860, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandez, H.H., Trieschmann, M.E. & Friedman, J.H. Treatment of Psychosis in Parkinson’s Disease. Drug-Safety 26, 643–659 (2003). https://doi.org/10.2165/00002018-200326090-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326090-00004

Keywords

Search

Navigation